Our study also demonstrated a substantial intertumoral heterogeneity in HER2-low tumors, with discrepancies in HER2 protein expression levels between the primary tumor and its metastases in a third of HER2-negative primary tumor cases (HER2 0, 1+, and 2+, non-amplified). Here, ERBB2 is linked to neoplasm.